Lung Neoplasm Malignant Clinical Trial
Official title:
Evaluation of Blood Tumor Mutation Burden (TMB) for Improved Efficacy of Atezolizumab in 2nd Line Non-small Cell Lung Cancer (NSCLC) [BUDDY]
This is single arm, prospective, multi-center, cohort study to evaluate blood TMB for improved efficacy of atezolizumab in locally advanced or metastatic NSCLC at the study enrollment who failed one or more prior lines of chemotherapy including at least 1 platinum-based.
Atezolizumab is approved as the treatment of patients with locally advanced or metastatic NSCLC who have disease progression during or following platinum-containing chemotherapy by the Ministry of Food and Drug Safety (MFDS) and the treatment is available on the National Health Insurance Service in South Korea. Patients will be treated with atezolizumab until loss of clinical benefit or unmanageable toxicity as routine practice. In this study, the investigators will register patients who have a plan to be treated with atezolizumab as MFDS approval condition and meet study inclusion and exclusion criteria. The investigators will collect study related information during routine practice and collect blood and/or tissue(optional) samples to conduct the study. Tumor assessment will be performed by investigator on the base of RECIST (version 1.1) and related information will be collected until disease progression for patients who have discontinued treatment. However, it will be collected until treatment discontinuation for patients who continue to receive atezolizumab following initial disease progression. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05890872 -
Aliyaâ„¢ Pulsed Electric Fields (PEF) for Advanced Cancer
|
N/A | |
Recruiting |
NCT05974475 -
MONDRIAN: Multi-omics Integrative Modelling for Stereotactic Body Radiotherapy in Early-stage Non-small Cell Lung Cancer
|
||
Recruiting |
NCT06079970 -
Confocal Laser Endomicroscopy VERification
|
N/A | |
Recruiting |
NCT04973293 -
Preoperative Sintilimab Combined With Bevacizumab and Chemotherapy for Resectable Non-Small Cell Lung Cancer
|
N/A | |
Recruiting |
NCT04778826 -
Immune Response Following Lobectomy Along With or Without Bilateral Transcervical Mediastinal Lymphadenectomy
|
N/A | |
Suspended |
NCT04036721 -
Coorticosteroid Regimen in Patients With Anti-PD-1/PD-L1 Induced Pneumonitis
|
Phase 4 | |
Completed |
NCT03352245 -
Feasibility of an Activity Regimen in Patients With Advanced Stage Lung Cancer
|
N/A | |
Completed |
NCT03834116 -
Resistance Inspiratory Muscle Training for Patients With Thoracic Malignancies
|
N/A | |
Completed |
NCT03824977 -
Prognostic Value of the 6-minute Stepper Test in Non-small Cell Lung Cancer Surgery
|
||
Terminated |
NCT02985203 -
Oral Navelbine and Cisplatin Followed by Metronomic Oral Navelbine in Non-Small Cell Lung Cancer
|
Phase 2 | |
Recruiting |
NCT06440616 -
Benefit of Spectral Information in Patients Suspected for Lung Cancer
|
N/A | |
Active, not recruiting |
NCT05241873 -
(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations
|
Phase 1/Phase 2 | |
Completed |
NCT05404022 -
Feasibility Trial of a Personalised Nutrition and Activity Programme for People With Lung Cancer Over 65 Years
|
N/A | |
Not yet recruiting |
NCT05414188 -
Beneficial Effect of Pulmonary Rehabilitation in Lung Cancer Patients Receiving Radiation Therapy
|
N/A | |
Recruiting |
NCT03525782 -
Anti-MUC1 CAR T Cells and PD-1 Knockout Engineered T Cells for NSCLC
|
Phase 1/Phase 2 | |
Terminated |
NCT05013554 -
Dose Escalation and Expansion Study of SAR443216 in Participants With Relapsed/Refractory HER2 Expressing Solid Tumors
|
Phase 1 |